Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 15/20 | 0.44 |
| ▸ | SRPK1 | Q96SB4 | 2/20 | 0.37 |
| ▸ | HTR5A | P47898 | 1/20 | 0.36 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | SRPK3 | Q9UPE1 | 1/20 | 0.35 |
| ▸ | SRPK2 | P78362 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL408023 | 0.86 | PTK2 (0.54) | PTK2SRPK1PTK2BSRPK3SRPK2 | |
| Hydrochloric Acid SCHEMBL30468512 | 0.84 | PTK2 (0.53) | PTK2SRPK1PTK2BSRPK3SRPK2 | |
| Hydrochloric Acid SCHEMBL29051922 | 0.84 | PTK2 (0.53) | PTK2SRPK1PTK2BSRPK3SRPK2 | |
| SCHEMBL17993894 | 0.82 | PTK2 (0.40) | PTK2SRPK1DPP4SRPK2 | |
| Acetic Acid SCHEMBL1627284 | 0.80 | PTK2 (0.49) | PTK2SRPK1PTK2B | |
| SCHEMBL6191568 | 0.78 | DPP4 (0.42) | PTK2DPP4 | |
| Hydrochloric Acid SCHEMBL30209077 | 0.76 | DPP4 (0.41) | PTK2DPP4 | |
| SCHEMBL1291246 | 0.74 | ALDH1A1 (0.39) | PTK2SRPK1DPP4 | |
| SCHEMBL4117490 | 0.73 | KDM4E (0.39) | PTK2DPP4 | |
| SCHEMBL10229210 | 0.72 | PTK2 (0.53) | PTK2SRPK1PTK2BSRPK3SRPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234303-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234303-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | CCNB1, TYMS, CCNA1 | PTK2 2406/4885SRPK1 218/4885HTR5A 2959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.